Condition
Velocardiofacial Syndrome
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (1)
P 4 (1)
Trial Status
Completed3
Terminated1
Recruiting1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00768820Phase 4RecruitingPrimary
The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome
NCT01127503Phase 2TerminatedPrimary
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
NCT00105274Completed
Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study
NCT00917189Not ApplicableCompletedPrimary
Computerized Cognitive Skills Training for Adolescents With Velocardiofacial Syndrome
NCT01781923Not ApplicableCompleted
Cognitive Remediation in 22q11DS
Showing all 5 trials